Stock 6628 TRANSCENTA HOLDING LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Transcenta Holding Limited Stock

Equities

6628

KYG9005B1041

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 EDT 		5-day change 1st Jan Change
1.78 HKD +1.71% Intraday chart for Transcenta Holding Limited +5.95% -50.42%
04-09 Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic MT
04-09 Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial CI

Financials

Sales 2024 * 161M 22.28M 174M 30.46M Sales 2025 * 176M 24.33M 190M 33.26M Capitalization 670M 92.47M 724M 126M
Net income 2024 * -309M -42.64M -334M -58.3M Net income 2025 * -457M -63.07M -494M -86.22M EV / Sales 2024 * 5.53 x
Net Debt 2024 * 222M 30.69M 240M 41.95M Net cash position 2025 * 455M 62.86M 492M 85.93M EV / Sales 2025 * 1.22 x
P/E ratio 2024 *
-2.17 x
P/E ratio 2025 *
-1.5 x
Employees 215
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.72%
More Fundamentals * Assessed data

Chart Transcenta Holding Limited

Dynamic Chart

Latest news about Transcenta Holding Limited

Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic MT
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial CI
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal MT
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging CI
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet MT
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain CI
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment MT
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients CI
Transcenta Widens Loss in H1 MT
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023 CI
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab) CI
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication MT
More news

Analyst Recommendations on Transcenta Holding Limited

Transcenta's Gastroesophageal Cancer Treatment Trial Sees 100% Disease Control Rate; Shares Tumble 3% MT
More recommendations

Press releases Transcenta Holding Limited

Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference. PR
Transcenta's Osemitamab Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer AQ
Transcenta to Present Two Preclinical Studies at AACR 2023 AQ
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors AQ
Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call PR
More press releases

Quotes and Performance

1 day+1.71%
1 week+5.95%
Current month-14.42%
1 month-16.43%
3 months-47.49%
6 months-55.05%
Current year-50.42%
More quotes

Highs and lows

1 week
1.55
Extreme 1.55
1.79
1 month
1.17
Extreme 1.17
2.09
Current year
1.17
Extreme 1.17
4.00
1 year
1.17
Extreme 1.17
6.20
3 years
1.17
Extreme 1.17
16.18
5 years
1.17
Extreme 1.17
16.18
10 years
1.17
Extreme 1.17
16.18
More quotes

Managers and Directors - Transcenta Holding Limited

Managers TitleAgeSince
Xue Ming Qian FOU
 Founder 57 10-07-31
Xiao Lu Weng DFI
 Director of Finance/CFO 47 21-12-16
Caroline Germa CTO
 Chief Tech/Sci/R&D Officer 52 22-08-07
Members of the board TitleAgeSince
Yi Ning Zhao FOU
 Founder 53 18-11-30
Xue Ming Qian FOU
 Founder 57 10-07-31
Jia Song Tang BRD
 Director/Board Member 50 21-09-13
More insiders

Quotes

Date Price Change Volume
24-04-26 1.78 +1.71% 154,500
24-04-25 1.75 0.00% 113,680
24-04-24 1.75 +3.55% 5,500
24-04-23 1.69 +2.42% 72,500
24-04-22 1.65 -1.79% 51,500

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am

More quotes

Company Profile

Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
Sector
Pharmaceuticals
Calendar
2024-08-25 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Transcenta Holding Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.648 CNY
Average target price
7.58 CNY
Spread / Average Target
+360.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TRANSCENTA HOLDING LIMITED Stock Transcenta Holding Limited
-50.42% 92.46M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6628 Stock